Skip to main
BBOT

BBOT Earnings Dates & Reports

BBOT Most Recent Earnings

Report Date
Period EndingQ4 2025
Est. EPS-$0.66
Actual EPS-$0.49
EarningsBeat

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

BBOT Earnings per Share (EPS) History

Signup for full access
Browse free

BBOT Latest Earnings

The value each BBOT share was expected to gain vs. the value each share gained.

BBOT reported its most recent earnings on for Q4 2025, posting earnings per share (EPS) of -$0.49. This exceeded analysts' expectations of -$0.66 by 25.76%, marking a Beat.

For comparison, BridgeBio Oncology Therapeutics Inc reported EPS of $0 in the same quarter last year.

The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$0.59.

BBOT Earnings History

Earnings
Est. EPSActual EPSSurprise
Q1 2026
-$0.59
Q4 2025
-$0.66-$0.49-25.76%

BBOT Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the BridgeBio Oncology Therapeutics Inc’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange

BBOT Earnings FAQs

BBOT last reported earnings on Mar 5, 2026 for Q4 2025, posting an EPS of -$0.49, which Beat the estimate of -$0.66 by 25.76%.

For Q4 2025, BBOT reported an EPS of -$0.49, exceeding analysts' estimate of -$0.66 by 25.76%.

For Q4 2025, BBOT Beat expectations with an actual EPS of -$0.49 vs. an estimated EPS of -$0.66.

Following the last earnings report on Mar 5, 2026, BBOT's stock price moved — from — to —.

The next BBOT earnings call is scheduled for May. 26, 2026, where executives will discuss financial results and outlook.

BridgeBio Oncology Therapeutics Inc (BBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.